SIGY (Sigyn Therapeutics) Tariff Resilience Score: 6/10 (As of Jul. 07, 2026)


What is Sigyn Therapeutics Tariff Resilience Score?

Sigyn Therapeutics SIGY -2.50% Tariff Resilience Score is 6 as of Jul. 07, 2026. The stock has 3 warning signs investors should review. Among 1,368 Biotechnology companies, Sigyn Therapeutics ranks better than 75.95% on this metric.

Sigyn Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Sigyn Therapeutics has Sigyn Therapeutics is in the early stages of development with potential global supply chain dependencies. Tariff impacts could affect future manufacturing and distribution, but current exposure is limited.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Sigyn Therapeutics might have Average Resilient.

Sigyn Therapeutics  (OTCPK:SIGY) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Sigyn Therapeutics Tariff Resilience Score Related Terms

SIGY vs RGBP, ENDV, VRTX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Sigyn Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sigyn Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sigyn Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Sigyn Therapeutics's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 6 mean?
Sigyn Therapeutics (SIGY) has a Tariff Resilience Score of 6 as of Jul. 07, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Sigyn Therapeutics ranks #329 out of 1368 companies in the Biotechnology industry, placing it in the top 24%.
Is Sigyn Therapeutics' Tariff Resilience Score too high?
Sigyn Therapeutics' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Sigyn Therapeutics' value of 6 is 50% above this industry median. Based on the distribution chart, Sigyn Therapeutics ranks #329 out of 1368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Sigyn Therapeutics' Tariff Resilience Score compare to RGBP and ENDV?
According to the Biotechnology industry distribution chart, Sigyn Therapeutics ranks #329 out of 1368 companies for Tariff Resilience Score. This places Sigyn Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Sigyn Therapeutics' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sigyn Therapeutics's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sigyn Therapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sigyn Therapeutics stock overvalued right now?
Sigyn Therapeutics (SIGY) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Sigyn Therapeutics (SIGY), the current Tariff Resilience Score is 6 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sigyn Therapeutics Business Description

Address 2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106
Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths world-wide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the world-wide infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.